Position in CDXS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$79,095
+$22,049 QoQ
Shares Held
34,998
0.0% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#74
of 148 holders
Holding Since
Mar 2020
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in CDXS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BANK OF MONTREAL /CAN/ holds $701,516,965 across 82 Biotechnology names. CDXS ranks #74 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
427,448 | $212,326,240 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
942,432 | $73,764,150 | |
| 3 | ARGX |
Argenx SE
|
77,213 | $71,635,902 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
103,247 | $64,378,631 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
242,063 | $58,329,919 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
515,981 | $28,347,995 | |
| 7 | MRNA |
Moderna, Inc.
|
389,789 | $27,296,921 | |
| 8 | CYTK |
Cytokinetics Inc
|
285,688 | $24,337,759 |
All Filings in CDXS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $79,095 | 34,998 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $57,046 | 34,998 | Shares | Defined | 2026-05-13 | |
| 2022-09-30 | $1,377,491 | 227,309 | Shares | Defined | 2022-11-10 | |
| 2022-06-30 | $3,480,238 | 332,719 | Shares | Defined | 2022-08-11 | |
| 2021-12-31 | $820,305 | 26,233 | Shares | Defined | 2022-02-11 | |
| 2021-03-31 | $88,217 | 3,854 | Shares | Defined | 2021-05-13 | |
| 2020-12-31 | $220,810 | 10,115 | Shares | Defined | 2021-02-12 | |
| 2020-09-30 | $44,447 | 3,786 | Shares | Defined | 2020-11-12 | |
| 2020-06-30 | $63,771 | 5,594 | Shares | Defined | 2020-08-12 | |
| 2020-03-31 | $14,496 | 1,299 | Shares | Defined | 2020-05-13 | |
| No filing history on record for this holder in this stock. | ||||||